Poor-quality antimalarials further health inequities in Uganda.
Malaria
Uganda
agent-based model
antimalarial
falsified
health inequities
quality
substandard
Journal
Health policy and planning
ISSN: 1460-2237
Titre abrégé: Health Policy Plan
Pays: England
ID NLM: 8610614
Informations de publication
Date de publication:
01 Dec 2019
01 Dec 2019
Historique:
revised:
13
09
2018
accepted:
13
02
2019
entrez:
10
12
2019
pubmed:
10
12
2019
medline:
28
4
2020
Statut:
ppublish
Résumé
Substandard and falsified medications are a major threat to public health, directly increasing the risk of treatment failure, antimicrobial resistance, morbidity, mortality and health expenditures. While antimalarial medicines are one of the most common to be of poor quality in low- and middle-income countries, their distributional impact has not been examined. This study assessed the health equity impact of substandard and falsified antimalarials among children under five in Uganda. Using a probabilistic agent-based model of paediatric malaria infection (Substandard and Falsified Antimalarial Research Impact, SAFARI model), we examine the present day distribution of the burden of poor-quality antimalarials by socio-economic status and urban/rural settings, and simulate supply chain, policy and patient education interventions. Patients incur US$26.1 million (7.8%) of the estimated total annual economic burden of substandard and falsified antimalarials, including $2.3 million (9.1%) in direct costs and $23.8 million (7.7%) in productivity losses due to early death. Poor-quality antimalarials annually cost $2.9 million to the government. The burden of the health and economic impact of malaria and poor-quality antimalarials predominantly rests on the poor (concentration index -0.28) and rural populations (98%). The number of deaths among the poorest wealth quintile due to substandard and falsified antimalarials was 12.7 times that of the wealthiest quintile, and the poor paid 12.1 times as much per person in out-of-pocket payments. Rural populations experienced 97.9% of the deaths due to poor-quality antimalarials, and paid 10.7 times as much annually in out-of-pocket expenses compared with urban populations. Our simulations demonstrated that interventions to improve medicine quality could have the greatest impact at reducing inequities, and improving adherence to antimalarials could have the largest economic impact. Substandard and falsified antimalarials have a significant health and economic impact, with greater burden of deaths, disability and costs on poor and rural populations, contributing to health inequities in Uganda.
Identifiants
pubmed: 31816072
pii: 5670622
doi: 10.1093/heapol/czz012
pmc: PMC6901073
doi:
Substances chimiques
Antimalarials
0
Counterfeit Drugs
0
Types de publication
Journal Article
Langues
eng
Pagination
iii36-iii47Informations de copyright
© The Author(s) 2019. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.
Références
PLoS One. 2010 Jul 30;5(7):e11759
pubmed: 20689585
Trop Med Int Health. 2008 Jun;13(6):771-83
pubmed: 18363586
Trends Pharmacol Sci. 2010 Mar;31(3):99-101
pubmed: 20117849
Lancet. 2004 Nov 27-Dec 3;364(9449):1950-7
pubmed: 15567011
Clin Infect Dis. 2009 Dec 1;49(11):1629-37
pubmed: 19877969
PLoS One. 2009 Nov 17;4(11):e7871
pubmed: 19936217
PLoS Med. 2006 Jun;3(6):e197
pubmed: 16752952
Malar J. 2016 Apr 27;15:246
pubmed: 27121122
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
PLoS One. 2008 May 07;3(5):e2132
pubmed: 18461128
J Trop Pediatr. 2010 Dec;56(6):379-85
pubmed: 20167633
Malar J. 2011 Dec 13;10:352
pubmed: 22152094
Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):75-86
pubmed: 25897065
Am J Trop Med Hyg. 2005 May;72(5):573-80
pubmed: 15891132
Int Arch Med. 2012 Mar 22;5(1):12
pubmed: 22439685
Am J Trop Med Hyg. 2010 Sep;83(3):465-73
pubmed: 20810805
Milbank Mem Fund Q Health Soc. 1982 Summer;60(3):429-62
pubmed: 6923138
Trop Med Int Health. 2008 Jan;13(1):108-22
pubmed: 18291009
Lancet. 2005 Apr 23-29;365(9469):1467-73
pubmed: 15850630
PLoS Med. 2005 Jul;2(7):e190
pubmed: 16033307
BMJ Open. 2013 Aug 17;3(8):e002923
pubmed: 23955188
BMJ. 2009 Jul 21;339:b2763
pubmed: 19622553
Lancet. 2010 Nov 13;376(9753):1647-57
pubmed: 21062666
Lancet Infect Dis. 2012 Jun;12(6):488-96
pubmed: 22632187
Expert Rev Anti Infect Ther. 2015 Apr;13(4):505-9
pubmed: 25683870
Trop Med Int Health. 2004 Apr;9(4):445-50
pubmed: 15078262
Malar J. 2011 Dec 19;10:372
pubmed: 22182735
Malar J. 2014 Dec 16;13:500
pubmed: 25515943
PLoS One. 2017 Dec 15;12(12):e0189758
pubmed: 29244829
Res Soc Stratif Mobil. 2011 Sep 1;29(3):343-349
pubmed: 22043133
Health Policy Plan. 2005 Nov;20(6):337-46
pubmed: 16155065
PLoS One. 2008 Jun 11;3(6):e2390
pubmed: 18545692
Antimicrob Agents Chemother. 2011 Jun;55(6):2629-35
pubmed: 21383095
PLoS One. 2013;8(1):e53772
pubmed: 23349741
Bull World Health Organ. 2011 Jul 1;89(7):504-12
pubmed: 21734764
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15
pubmed: 15331814
PLoS One. 2015 Jul 27;10(7):e0134275
pubmed: 26214848
J Clin Pharm Ther. 2007 Oct;32(5):429-40
pubmed: 17875107
Lancet Infect Dis. 2010 Nov;10(11):762-9
pubmed: 20932805
Afr Health Sci. 2003 Apr;3(1):2-6
pubmed: 12789081
PLoS Med. 2011 Nov;8(11):e1001119
pubmed: 22087077
PLoS Clin Trials. 2006 May;1(1):e7
pubmed: 16871329
Malar J. 2014 Nov 23;13:452
pubmed: 25418416
Int J Equity Health. 2009 Dec 23;8:45
pubmed: 20030827
PLoS One. 2015 May 27;10(5):e0125577
pubmed: 26018221
Prog Biophys Mol Biol. 2013 Sep;113(1):80-91
pubmed: 23542650
JAMA Netw Open. 2018 Aug 3;1(4):e181662
pubmed: 30646106
Emerg Infect Dis. 2016 Aug;22(8):1494-8
pubmed: 27434741
Malar J. 2019 Jan 9;18(1):5
pubmed: 30626380
Clin Infect Dis. 2013 Mar;56(5):e48-58
pubmed: 23175556
Malar J. 2011 May 18;10:134
pubmed: 21592380
Am J Trop Med Hyg. 2019 May;100(5):1149-1157
pubmed: 30675851
N Engl J Med. 2016 Dec 22;375(25):2416-2417
pubmed: 28002698